Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Last updated: August 26, 2024
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

2

Condition

Kidney Transplantation

Transplant Rejection

Treatment

Tocilizumab

Clinical Study ID

NCT04779957
RC31/19/0511
  • Ages > 18
  • All Genders

Study Summary

Graft nephrectomy is associated with massive allo-sensitization following this event. The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Investigators propose here to evaluate in a phase II pilot study, the safety of the use of a single dose of Tocilizumab immediately before or after graft nephrectomy. The primary endpoint evaluated here is the occurrence of serious infectious complications following graft nephrectomy, with a treatment by Tocilizumab. Secondary endpoints evaluated here are - to evaluate all complications after graft nephrectomy, - and the Tocilizumab effectiveness to reduce anti-HLA antibodies at one year post nephrectomy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult recipients,

  • affiliated to the social security

  • requiring a graft nephrectomy, with a project to retransplantation

Exclusion

Exclusion Criteria:

  • combined transplantations, PRA >20%.

  • Patient under protective measures,

  • Rituximab used for immunosuppression induction

  • Previous transplants not removed,

  • Active infectious complications at graft nephrectomy, need for immunosuppressivetreatments after graft nephrectomy,

  • Participation to another interventional studies using Rituximab, polyclonalantibodies, Eculizumab, or Tocilizumab.

  • adults under guardianship or other legal protection, deprived of their liberty byjudicial or administrative decision,

  • pregnancy or breastfeeding.

Study Design

Total Participants: 18
Treatment Group(s): 1
Primary Treatment: Tocilizumab
Phase: 2
Study Start date:
October 01, 2021
Estimated Completion Date:
October 31, 2024

Study Description

Background: graft nephrectomy is associated with massive allo-sensitization following this event The occurrence of anti-HLA antibodies is a major barrier to perform a second kidney transplantation. Moreover, a systemic inflammatory response syndrome can occur which could lead to serious patient's complications, in case of early graft thrombosis. To date, no treatment or strategy is available to reduce these risks, after graft nephrectomy. IL-6 is a key cytokine in inflammation, but also in the development of T and B cells activation. This treatment previously demonstrated a major role in the occurrence of allo-antibodies. Tocilizumab is a monoclonal antibody blocking IL6 receptor, previously used with success in kidney transplantation to reduce anti-HLA antibodies mediated rejection.

Objectives: Investigators hypothesize that Tocilizumab is useful to prevent allo-sensitization post graft nephrectomy. They propose here to evaluate in a phase II pilot study, the safety of the use of a single dose of Tocilizumab immediately before or after graft nephrectomy.

Connect with a study center

  • CHU Toulouse

    Toulouse,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.